Handelsbanken Fonder AB Has $1.89 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Handelsbanken Fonder AB grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,600 shares of the biotechnology company’s stock after buying an additional 700 shares during the quarter. Handelsbanken Fonder AB’s holdings in United Therapeutics were worth $1,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock valued at $1,053,212,000 after acquiring an additional 20,373 shares in the last quarter. LSV Asset Management raised its stake in shares of United Therapeutics by 1.0% in the 3rd quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company’s stock valued at $86,524,000 after acquiring an additional 3,700 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of United Therapeutics by 27.6% in the 4th quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock valued at $68,781,000 after acquiring an additional 67,738 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of United Therapeutics by 30.9% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 260,412 shares of the biotechnology company’s stock valued at $58,819,000 after acquiring an additional 61,543 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of United Therapeutics by 1.1% in the 3rd quarter. California Public Employees Retirement System now owns 257,551 shares of the biotechnology company’s stock valued at $58,173,000 after acquiring an additional 2,887 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Down 0.9 %

Shares of UTHR opened at $233.85 on Friday. The stock has a market cap of $11.00 billion, a price-to-earnings ratio of 11.79 and a beta of 0.52. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a 50-day moving average price of $233.74 and a two-hundred day moving average price of $228.81.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.67 earnings per share. Equities analysts predict that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 136,990 shares of company stock valued at $32,239,641. Corporate insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.